Guobang Pharma (605507) Fundamentals 2026 — P/E 11.7x, Revenue Analysis | SniperIQ
Guobang Pharma (605507) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥12.7B, trading at ¥16.27 on the SHH. This SniperIQ fundamentals page covers Guobang Pharma's valuation (P/E 11.7x, P/B 1.0x), profitability (net margin 12.6%), revenue (¥6.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Guobang Pharma's market cap?
Guobang Pharma (605507) has a market capitalization of approximately ¥12.7B, trading at ¥16.27 on the SHH. Market cap moves with the live share price.
What is Guobang Pharma's P/E ratio?
Guobang Pharma's trailing twelve-month P/E ratio is 11.7x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Guobang Pharma?
Guobang Pharma runs a net profit margin of 12.6%, a gross margin of 24.7%, and an operating margin of 14.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Guobang Pharma generate?
Guobang Pharma reported revenue of ¥6.0B for fiscal year 2025, with net income of ¥821M and earnings per share (EPS) of 1.48. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Guobang Pharma pay a dividend?
Guobang Pharma offers a trailing dividend yield of about 3.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Guobang Pharma financially healthy?
Guobang Pharma carries a debt-to-equity ratio of 0.22x and a current ratio of 2.54x, with a market beta of 0.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Guobang Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guobang Pharma (605507) the key facts are: market cap ¥12.7B, P/E 11.7x, revenue ¥6.0B, 52-week range 14.34-21.41429. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Guobang Pharma's full fundamentals live
Get Guobang Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.